Literature DB >> 34988623

Presence of tumour capsule on contrast-enhanced CT is associated with improved outcomes of stereotactic body radiation therapy in hepatocellular carcinoma patients.

Siu Hin Mak1, Sean Man Natalie Wong2, Wan Hang Keith Chiu3, Chi Leung Chiang4, Wing Ling Winnie Yip2, Hoi Man Connie Ho1, Sin Yu Cynthia Yeung1, Ka Heng Mark Chan5,6, Wan Yan Venus Lee1, Ann Shing Francis Lee1.   

Abstract

PURPOSE: Stereotactic body radiation therapy (SBRT) is a novel local therapy for the treatment of hepatocellular carcinoma (HCC). While effective, there is currently no reliable radiological marker to guide patient selection. In this study, we investigated the prognostic value of capsule appearance on contrast-enhanced computed tomography (CT) for patients undergoing SBRT.
MATERIALS AND METHODS: Between 2006 and 2017, 156 consecutive patients with Child-Pugh score class A/B and HCC ≥ 5 cm who underwent SBRT were retrospectively analysed. Baseline triple-phase CTs of the abdomen were reviewed for the presence of capsule appearances and correlated with objective response rate (ORR), overall survival (OS) and pattern of treatment failure.
RESULTS: Capsule appearance on CT was present in 83 (53.2%) patients. It was associated with improved ORR by Response Evaluation Criteria in Solid Tumours (RECIST) (60.2 vs. 24.7%, p < 0.001) and Modified Response Evaluation Criteria in Solid Tumours (mRECIST) (78.3 vs. 34.2%, p < 0.001). The presence of a capsule was also associated with superior 2‑year local control (89.1 vs. 51.4%, p < 0.001) and 2‑year OS (34.1 vs. 14.8%, p < 0.01). Hepatic out-field failure was the dominant mode of progression, which was less common in patients with intact capsule (54.2 vs. 60.3%, p = 0.01).
CONCLUSION: Capsule appearance on CT could potentially be a non-invasive prognostic marker for selecting HCC patients to undergo SBRT. A larger cohort is warranted to validate our findings.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Imaging; Local control; Overall survival; Precision medicine; Radiological prognostic marker

Mesh:

Year:  2022        PMID: 34988623     DOI: 10.1007/s00066-021-01879-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   4.033


  30 in total

1.  Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants.

Authors:  Angelo Luca; Settimo Caruso; Mariapina Milazzo; Giuseppe Mamone; Gianluca Marrone; Roberto Miraglia; Luigi Maruzzelli; Vincenzo Carollo; Marta Ida Minervini; Giovanni Vizzini; Salvatore Gruttadauria; Salvatore Grutttadauria; Bruno Gridelli
Journal:  Eur Radiol       Date:  2009-10-03       Impact factor: 5.315

2.  Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.

Authors:  Po-Chien Shen; Wei-Chou Chang; Cheng-Hsiang Lo; Jen-Fu Yang; Meei-Shyuan Lee; Yang-Hong Dai; Chun-Shu Lin; Chao-Yueh Fan; Wen-Yen Huang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-06-05       Impact factor: 7.038

Review 3.  Radiological features of hepatocellular carcinoma.

Authors:  Samir Shah; Akash Shukla; Bhawan Paunipagar
Journal:  J Clin Exp Hepatol       Date:  2014-07-19

4.  Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.

Authors:  Chai Hong Rim; Hyun Ju Kim; Jinsil Seong
Journal:  Radiother Oncol       Date:  2018-12-31       Impact factor: 6.280

5.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

Review 6.  Epidemiology of hepatocellular carcinoma.

Authors:  Kelly J Lafaro; Aram N Demirjian; Timothy M Pawlik
Journal:  Surg Oncol Clin N Am       Date:  2014-10-03       Impact factor: 3.495

7.  Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma.

Authors:  Ting-Shi Su; Ping Liang; Jian Liang; Huan-Zhen Lu; Hua-Yan Jiang; Tao Cheng; Yong Huang; Yang Tang; Xin Deng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-03-01       Impact factor: 7.038

Review 8.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 9.  Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients.

Authors:  Victoria Chernyak; Kathryn J Fowler; Aya Kamaya; Ania Z Kielar; Khaled M Elsayes; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Amit G Singal; An Tang; Claude B Sirlin
Journal:  Radiology       Date:  2018-09-25       Impact factor: 11.105

10.  Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities.

Authors:  Pegah Golabi; Sofie Fazel; Munkhzul Otgonsuren; Mehmet Sayiner; Cameron T Locklear; Zobair M Younossi
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.